HomeBiosimilar Antibodies

Biosimilar Antibodies

Cat.No. Product Name Information Isotype
A2635 Sotigalimab (Anti-TNFRSF5 / CD40) Sotigalimab (Anti-TNFRSF5 / CD40) is an agonistic monoclonal antibody targeting CD40. It can be used for the research of metastatic pancreatic adenocarcinoma.MW :144.54 KD. Human IgG1
A2891 Matuzumab (Anti-ERBB1 / EGFR / HER1) Matuzumab (anti-ERBB1/ EGFR / HER1) is a humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody that blocks EGFR activation, downstream signalling, and inhibits tumor growth. MW: 145.9 KD. Human IgG1
A3147 Anti-AA2AR / Adenosine A2aR (3F6-9G5) Anti-AA2AR / Adenosine A2aR (3F6-9G5) is a monoclonal antibody targeting A2A adenosine receptor. It may be an attractive target for research studies or treatments of insomnia, pain, depression, and Parkinson's disease. MW :146.66 KD. Human IgG1
A2636 Dacetuzumab (Anti-TNFRSF5 / CD40) Dacetuzumab (Anti-TNFRSF5 / CD40) is a humanized IgG1, monoclonal antibody targeting CD40. Ithas anti-lymphoma activity and can be used for multiple myeloma research. MW :150 KD. Human IgG1
A2892 Golimumab (Anti-TNFSF2 / TNFa) Golimumab (Anti-TNFSF2 / TNFa) is a human monoclonal antibody directed against the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-a) with immunosuppressive activity. MW: 146.94 KD. Human IgG1
A3148 Anti-BTN1A1 (ICT-01) Anti-BTN1A1 (ICT-01-N297A) is a humanized monoclonal antibody targeting BTN1A1. It can be used in treatment of advanced solid tumors. MW :146.2 KD. Human IgG1
A2637 Anti-CD47 (CC-90002) Anti-CD47 (CC-90002) is a humanized monoclonal antibody (mAb) targeting CD47. It can be used for the research of hematologic malignancies and solid tumors. MW :150 KD. Human IgG4SP
A2893 Pimurutamab (Anti-ERBB1 / EGFR / HER1) Pimurutamab (Anti-ERBB1 / EGFR / HER1) is a glycoengineered humanized monoclonal antibody against epidermal growth factor receptor (EGFR) potential antineoplastic activity. MW: 144.92 KD. Human IgG1
A3149 Anti-BTN1A1 (ICT-01-N297A) Anti-BTN1A1 (ICT-01) is a humanized monoclonal antibody targeting BTN1A1. It can be used in treatment of advanced solid tumors. MW :146.2 KD. Human IgG1
A2638 Labetuzumab (Anti-CEACAM5 / CEA / CD66e) Labetuzumab (Anti-CEACAM5 / CEA / CD66e) is a humanised monoclonal antibody targeting carcinoembryonic antigen (CEA). It inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy. MW :145.36 KD. Human IgG1
A2639 Anti-CEACAM6 / CD66c (NEO-201) Anti-CEACAM6 / CD66c (NEO-201) is a humanized IgG1 monoclonal antibody that targets of CEACAM family. It enhances natural killer cell cytotoxicity against tumor cells. MW :145.48 KD. Human IgG1
A2895 Zalutumumab (Anti-ERBB1 / EGFR / HER1) Zalutumumab (Anti-ERBB1 / EGFR / HER1) is a fully human IgG1 monoclonal antibody against epidermal growth factor receptor (EGFR) with potential antineoplastic activity. MW: 146.52 KD. Human IgG1
A2640 Anti-CHI3L1 Anti-CHI3L1 is a monoclonal antibody targeting Chitinase 3–like 1 (CHI3L1). It proves a promising therapy for pulmonary metastasis and progression. MW :147.04 KD. Human IgG1
A2641 Anti-DCBLD2 / ESDN (FA19-1) Anti-DCBLD2 / ESDN (FA19-1) is a polyclonal antibody that targets the DCBLD2. It inhibits tumor metastasis in lung adenocarcinoma (LUAD). MW :146.84 KD. Human IgG1
A2897 Ifabotuzumab (Anti-EphA3) Ifabotuzumab (Anti-EphA3) is a monoclonal antibody against EphA3. MW: 145.28 KD. Human IgG1
A2642 Zolbetuximab (Anti-CLDN18.2) Zolbetuximab (Anti-CLDN18.2) is a monoclonal antibody targeting Claudin-18.2. It can be used for the research of gastrointestinal adenocarcinomas and pancreatic tumors. MW :150 KD. Human IgG1
A2898 Hersintuzumab (Anti-ERBB2 / HER2 / CD340) Hersintuzumab (Anti-ERBB2 / HER2 / CD340) is a humanized monoclonal antibody that targets human epidermal growth factor receptor 2 (HER2), extracellular domains I–II, with antitumor activity in ovarian cancer. MW: 144.26 KD. Human IgG1
A3154 Anti-CDH17 / Cadherin-17 (10C12) Anti-CDH17 / Cadherin-17 (10C12) is a humanized monoclonal antibody targeting Cadherin-17 (CDH17), a prominent cancer biomarker. It has growth inhibitory effect on liver and stomach tumour cells. It can be used as therapeutics for treating lung metastasis of hepatocellular carcinoma (HCC). MW :143.68 KD. Human IgG1
A2643 Anti-CLDN6 (IMAB027) Anti-CLDN6 (IMAB027) is a fully humanized antibody targeting CLDN6. It gets conjugated to monomethyl auristatin E( MMAE) resulting in the potential therapeutic CLDN6–23-ADC. It exhibits antitumor efficacy in ovarian epithelial carcinomas.MW :144.42 KD. Human IgG1
A2899 Margetuximab (Anti-ERBB2 / HER2 / CD340) Margetuximab (Anti-ERBB2 / HER2 / CD340) is a Fc-domain optimized IgG monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2) with potential immunomodulating and antineoplastic activities. MW: 146.1 KD. Human IgG1